Acromegaly  >>  Signifor LAR (pasireotide long acting release)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Signifor LAR (pasireotide long acting release) / Recordati
PAPE, NCT02668172 / 2014-002219-41: Pasireotide LAR and Pegvisomant Study in Acromegaly

Unknown status
4
60
Europe
Pasireotide LAR 60 mg, Signifor, SOM230, Pegvisomant, Somavert
Erasmus Medical Center, Novartis
Acromegaly
03/17
06/17
NCT02060383 / 2012-002916-16: Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

Completed
4
249
US, Europe, RoW
Pasireotide s.c., SOM230, Sitagliptin, Liraglutide, Insulin, Pasireotide LAR, Metformin
Novartis Pharmaceuticals
Cushing's Disease, Acromegaly
02/18
03/18
NCT01794793 / 2013-000267-84: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Completed
4
337
Europe, Canada, Japan, US, RoW
Pasireotide, SOM230; Signifor, Cabergoline, dostinex, Pasireotide LAR
RECORDATI GROUP
Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS
07/23
07/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Signifor LAR (pasireotide long acting release) / Recordati
PAPE, NCT02668172 / 2014-002219-41: Pasireotide LAR and Pegvisomant Study in Acromegaly

Unknown status
4
60
Europe
Pasireotide LAR 60 mg, Signifor, SOM230, Pegvisomant, Somavert
Erasmus Medical Center, Novartis
Acromegaly
03/17
06/17
NCT02060383 / 2012-002916-16: Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

Completed
4
249
US, Europe, RoW
Pasireotide s.c., SOM230, Sitagliptin, Liraglutide, Insulin, Pasireotide LAR, Metformin
Novartis Pharmaceuticals
Cushing's Disease, Acromegaly
02/18
03/18
NCT01794793 / 2013-000267-84: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Completed
4
337
Europe, Canada, Japan, US, RoW
Pasireotide, SOM230; Signifor, Cabergoline, dostinex, Pasireotide LAR
RECORDATI GROUP
Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS
07/23
07/23

Download Options